Literature DB >> 26612314

Rapid clearance of circulating tumor DNA during treatment with AZD9291 of a lung cancer patient presenting the resistance EGFR T790M mutation.

Audrey Vallée1, Clarisse Audigier-Valette2, Guillaume Herbreteau1, Julien Merrien2, Laurent Tessonnier3, Sandrine Théoleyre1, Marc G Denis4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26612314     DOI： 10.1016/j.lungcan.2015.11.008

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


× No keyword cloud information.
  15 in total

1.  Editorial for "Longitudinal cell-free DNA analysis in patients with small cell lung cancer reveals dynamic insights into treatment efficacy and disease relapse".

Authors:  Michael Fleischhacker; Bernd Schmidt
Journal:  Transl Lung Cancer Res       Date:  2018-12

Review 2.  Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer.

Authors:  Joan Rou-En Choo; Chee-Seng Tan; Ross A Soo
Journal:  Target Oncol       Date:  2018-04       Impact factor: 4.493

3.  Circulating free tumor-derived DNA to detect EGFR mutations in patients with advanced NSCLC: French subset analysis of the ASSESS study.

Authors:  Marc G Denis; Marie-Pierre Lafourcade; Gwenaëlle Le Garff; Charles Dayen; Lionel Falchero; Pascal Thomas; Chrystèle Locher; Gérard Oliviero; Muriel Licour; Martin Reck; Nicola Normanno; Olivier Molinier
Journal:  J Thorac Dis       Date:  2019-04       Impact factor: 2.895

4.  Mutant KRAS Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring.

Authors:  Ruth Perets; Orli Greenberg; Talia Shentzer; Valeria Semenisty; Ron Epelbaum; Tova Bick; Shada Sarji; Ofer Ben-Izhak; Edmond Sabo; Dov Hershkovitz
Journal:  Oncologist       Date:  2018-01-25

5.  Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells.

Authors:  Jun Lu; Wei Xu; Jie Qian; Shuyuan Wang; Bo Zhang; Lele Zhang; Rong Qiao; Minjuan Hu; Yiming Zhao; Xiaodong Zhao; Baohui Han
Journal:  BMC Med Genomics       Date:  2019-03-13       Impact factor: 3.063

6.  Current progress and outcomes of clinical trials on using epidermal growth factor receptor-tyrosine kinase inhibitor therapy in non-small cell lung cancer patients with brain metastases.

Authors:  Ling-Ling Kong; Lin-Lin Wang; Li-Gang Xing; Jin-Ming Yu
Journal:  Chronic Dis Transl Med       Date:  2017-12-12

7.  Efficient treatment of a metastatic melanoma patient with a combination of BRAF and MEK inhibitors based on circulating tumor DNA analysis: a case report.

Authors:  Gaelle Quéreux; Guillaume Herbreteau; Anne-Chantal Knol; Audrey Vallée; Amir Khammari; Sandrine Théoleyre; Mélanie Saint-Jean; Brigitte Dréno; Marc G Denis
Journal:  BMC Res Notes       Date:  2017-07-25

8.  Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.

Authors:  Victoria Villaflor; Brian Won; Rebecca Nagy; Kimberly Banks; Richard B Lanman; AmirAli Talasaz; Ravi Salgia
Journal:  Oncotarget       Date:  2016-10-11

Review 9.  Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer.

Authors:  Misako Nagasaka; Mohammed Hafiz Uddin; Mohammed Najeeb Al-Hallak; Sarah Rahman; Suresh Balasubramanian; Ammar Sukari; Asfar S Azmi
Journal:  Mol Cancer       Date:  2021-06-01       Impact factor: 27.401

10.  Clinical utility of circulating cell-free DNA in advanced colorectal cancer.

Authors:  Allan A Lima Pereira; Maria Pia Morelli; Michael Overman; Bryan Kee; David Fogelman; Eduardo Vilar; Imad Shureiqi; Kanwal Raghav; Cathy Eng; Shanequa Manuel; Shadarra Crosby; Robert A Wolff; Kimberly Banks; Richard Lanman; AmirAli Talasaz; Scott Kopetz; Van Morris
Journal:  PLoS One       Date:  2017-08-29       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.